Sano Genetics Receives £330K Grant to Aid Patients at Risk of Motor Neurone Disease

Sano Genetics, a start-up focused on personalised medicine and research, has secured a £330K grant from Innovate UK. The grant is intended to help the company develop a digital platform that can support patients at risk of developing Motor Neurone Disease (MND).

Innovate UK Fuels Sano Genetics’ MND Mission

The grant from Innovate UK, a public body funded by the UK government, is enabling Sano Genetics to advance its mission to support patients at risk of MND. The company aims to use this funding to develop a digital platform that can provide personalised healthcare and research for these patients.

Sano Genetics’ Digital Platform for MND

Sano Genetics is working on a digital platform that will provide personalised information and support to patients at risk of MND. This platform will enable patients to access their own personalised genetic information, which can be used to inform treatment decisions. The platform will also facilitate the collection of patient data for use in research studies.

The Impact of MND and the Role of Sano Genetics

Motor Neurone Disease is a devastating condition that affects the nerve cells in the brain and spinal cord. Sano Genetics’ work is critical in providing much-needed support to patients at risk of this disease. Their digital platform aims to empower patients with information about their genetic risk and facilitate the creation of a patient-led research community to accelerate the search for effective treatments.

The grant from Innovate UK adds significant weight to Sano Genetics’ mission to support patients at risk of MND. By developing a digital platform that personalizes information and support, the company is positioning itself at the forefront of patient-led research into this devastating disease.